

SUDA Pharmaceuticals Ltd

08:44 30 Jul 2020

SUDA Pharmaceuticals on hunt for complementary technologies and products to add to current programs

SUDA Pharmaceuticals Ltd (ASX:SUD) (FRA:E4N) is committed to driving its current programs and sourcing new technologies and products.


As part of this process, the company is considering acquiring or licensing life sciences technologies that can be added to its existing pipeline.

It is specifically looking for products that it can repurpose into oral sprays or products that are complementary to its portfolio of cancer and central nervous system (CNS) treatments such as immune-oncology assets or medications for

Price: 0.044

Market Cap: \$13.46 m

1 Year Share Price Graph



Share Information

Code: SUD

Listing: ASX

52 week High Low
0.097 0.0245694


Sector: Medical technology & services

Website: www.sudapharma.com

Company Synopsis:

SUDA Pharmaceuticals Ltd (ASX:SUD) is a drug delivery company focused on oromucosal administration. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals.

action@proactiveinvestors.com.au



migraine and insomnia.

Chief executive officer Michael Baker said the company was on the look-out for deals globally, but with specific interest in the US, Europe and Australia, Acuris Mergermarket reports.

\$3.5 million entitlement offer

The company launched a \$3.5 million entitlement offer to existing shareholders, which closes on Thursday, after calling off a proposed licensing deal pertaining to a cancer therapy technology from a leading cancer research institute.

This transaction may have resulted in the ASX declining its readmission, resulting in SUDA deciding against proceeding with both the deal and the accompanying capital raising.

Baker said the \$3.5 million funds raised in the entitlement offer to existing shareholders would go towards financing any potential deals, general working capital, as well as pay for the development of its existing pipeline.

This includes its anagrelide and the remaining OroMist assets.

Pipeline and new products

Given the decision not to move forward with the US oncology deal, SUDA has decided to continue to develop its existing technology in the oncology space.

It will also continue to progress its short-term insomnia treatment, ZolpiMist, for which the company this week received Therapeutics Goods Administration (TGA) approval for registration.

SUDA will continue to pursue the development of products together with partners Sanofi SA (NASDAQ:SNY) (EPA:SAN) Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) and Cann Pharmaceutical Australia.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).